Our Work
Latham & Watkins Advises 4D Molecular Therapeutics in License Agreement With Astellas Pharma
July 12, 2023
Healthcare & Life Sciences team represents the clinical-stage biotherapeutics company.
Astellas Pharma Inc. (TSE: 4503) and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) have announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100* vector invented by 4DMT for one genetic target implicated in rare monogenic ophthalmic disease(s), with options to add up to two additional targets implicated in rare monogenic ophthalmic diseases after paying additional option exercise fees.
Latham & Watkins LLP advised 4D Molecular Therapeutics in the agreement with a Healthcare & Life Sciences team led by Bay Area partners Chris Hazuka and Mark Roeder.